Luteolin for the Treatment of People With Schizophrenia

NARecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 13, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DIETARY_SUPPLEMENT

Luteolin

The luteolin target dose will be 300 mg BID taken over 12 weeks in capsule form

DIETARY_SUPPLEMENT

Placebo

The placebo target dose will be 300 mg BID taken over 12 weeks in capsule form

Trial Locations (2)

21228

COMPLETED

Maryland Psychiatric Research Center, Baltimore

90095

RECRUITING

University of California, Los Angeles, Los Angeles

All Listed Sponsors
collaborator

University of California, Los Angeles

OTHER

collaborator

Stanley Medical Research Institute

OTHER

lead

University of Maryland, Baltimore

OTHER